You are here

Report: Breast Cancer Market Set to Grow to More Than $15 Billion by 2022

New drugs will change the way many patients are treated (August 22)

Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the uptake of premium-priced drugs will fuel 5 percent annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., Europe, and Japan.

According to the new report, the uptake of Perjeta (pertuzumab, Genentech) and Kadcyla (ado-trastuzumab emtansine, Genentech) for HER2-positive disease, as well as the continued use of Afinitor (everolimus, Novartis) and the launch of palbociclib (Pfizer) for hormone receptor-positive disease will contribute to growth in the breast cancer market through 2022, off-setting sales erosion of key current therapies, such as Herceptin (trastuzumab, Genentech), that are due to lose patent protection over the next decade.

The report also finds that sales for HER2-positive breast cancer dominate the current market, accounting for 41 percent of major market sales in 2012, and will continue to do so through 2022, owing to the availability of several targeted agents specifically approved for this market segment.

The findings also reveal strong sales growth from agents positioned to treat hormone receptor-positive, HER2-negative breast cancer. The launch of Afinitor in this indication in 2011 as well as the anticipated approval of palbociclib will boost sales from this large market segment.

“New market entrants are set to change the way many breast cancer patients are treated by 2022,” said analyst Amy Duval. “The evolving HER2-positive market segment will see the incorporation of Perjeta and Kadcyla, diversifying the treatment options available for these patients at different stages of disease. Targeted therapies Afinitor and palbociclib will impact the way many advanced hormone receptor-positive patients are managed.”

Source: Decision Resources; August 22, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress